The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Weight loss isn't the only change Individuals who are taking a GLP-1 weight loss medicine are seeing. They also tend to spend less on groceries. That's the assessment from a recently published study ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration’s ...

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

More Americans are expected to try the drugs as a pill rather than as a shot because the medication will be cheaper and many patients are hesitant to inject themselves ...

Asian shares are mixed in thin holiday trading, with most markets in the region and elsewhere closed for Christmas ...

News you should know, including a really big Powerball jackpot; a salmonella outbreak linked to oysters; and more!

Live Updates Get The Best Affirm Live Earnings Coverage Like This Every Quarter Get earnings reminders, our top analysis on ...

About 14% of adults in Philadelphia have diabetes, one of the highest rates in the country, the city said, and Black and ...